Nurix Therapeutics, Inc.
NRIX · NASDAQ
11/30/2024 | 11/30/2023 | 11/30/2022 | 11/30/2021 | |
|---|---|---|---|---|
| Revenue | $55 | $77 | $39 | $30 |
| % Growth | -29.1% | 99.3% | 29.8% | – |
| Cost of Goods Sold | $222 | $189 | $184 | $116 |
| Gross Profit | -$167 | -$112 | -$146 | -$87 |
| % Margin | -306.3% | -145.7% | -377.6% | -291.4% |
| R&D Expenses | $222 | $189 | $184 | $116 |
| G&A Expenses | $46 | $43 | $38 | $31 |
| SG&A Expenses | $46 | $43 | $38 | $31 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$222 | -$189 | -$184 | -$116 |
| Operating Expenses | $46 | $43 | $38 | $31 |
| Operating Income | -$213 | -$155 | -$184 | -$118 |
| % Margin | -390.5% | -201.4% | -476% | -396.3% |
| Other Income/Exp. Net | $20 | $11 | $4 | $1 |
| Pre-Tax Income | -$193 | -$144 | -$180 | -$117 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$194 | -$144 | -$180 | -$117 |
| % Margin | -354.9% | -187% | -466.9% | -393.9% |
| EPS | -2.88 | -2.65 | -3.71 | -2.73 |
| % Growth | -8.7% | 28.6% | -35.9% | – |
| EPS Diluted | -2.88 | -2.65 | -3.71 | -2.73 |
| Weighted Avg Shares Out | 67 | 54 | 49 | 43 |
| Weighted Avg Shares Out Dil | 67 | 54 | 49 | 43 |
| Supplemental Information | – | – | – | – |
| Interest Income | $20 | $11 | $4 | $1 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $8 | $6 | $4 | $2 |
| EBITDA | -$205 | -$149 | -$180 | -$116 |
| % Margin | -375.8% | -193.4% | -465.3% | -389.6% |